Aprea Therapeutics, a Karolinska Institute spinout, is set to raise as much as $92m from an offering that would bank Karolinska Development a return of up to $8m.
Aprea Therapeutics, a US-based oncological therapeutics spinout of Karolinska Institute, aims to raise a maximum of $92m from its forthcoming public listing with a target price range of $14 to $16.
The company will issue 5 .75 million shares. Aprea originally envisaged raising proceeds of $68.3m when it filed for the initial public offering earlier this month.
Founded in 2003, Aprea Therapeutics is advancing cancer treatments that work by restoring functionality to mutated p53 tumour suppressor proteins,…
